Pharma VC Funds

Bessemer Venture Partners (BVP), headquartered in San Francisco, is one of the oldest venture capital firms in the United States. Established in 1911, BVP has a long history of investing in early- and growth-stage companies across various industries, including technology, healthcare, and consumer sectors. Some of their notable investments include Shopify, LinkedIn, DocuSign, Pinterest, and Yelp​. BVP is known for its systematic approach to venture capital, leveraging deep industry insights and a decentralized decision-making process. This allows individual partners significant autonomy to invest across different stages, industries, and geographies. The firm has offices not only in the U.S. but also in India, Israel, and the UK​. BVP has raised multiple funds over the years, including a $3.85 billion early-stage fund in 2021 and a $780 million buyout fund under BVP Forge in 2022. These funds reflect their strategy of supporting startups from inception through to growth and eventual exit​ . Their "Anti-Portfolio" is a unique feature on their website, showcasing major investment opportunities they missed, including companies like Apple and eBay, highlighting their commitment to transparency and learning from past decisions​ ​. With a focus on fostering innovation and supporting dynamic founders, Bessemer Venture Partners continues to be a significant player in the global venture capital landscape.

Beta Boom, headquartered in Salt Lake City, Utah, is a venture capital firm focused on pre-seed and seed investments in startups led by diverse and underrepresented founders. Established in 2017 by Kimmy and Sergio Paluch, Beta Boom prioritizes founders outside of the traditional Silicon Valley ecosystem, particularly women and people of color. The firm invests in companies across various sectors, including digital health, financial technology, education technology, and SaaS. Notable portfolio companies include Canopie, Valhalla Healthcare, and Bolder Money. Beta Boom provides extensive post-investment support, including weekly coaching in product development, marketing, sales, and fundraising, effectively becoming an extension of the startup teams they invest in. Beta Boom recently closed a $14.5 million Fund II, with support from partners such as Ally Bank, Pivotal Ventures, and Bank of America. This fund aims to support early-stage startups addressing the needs of fast-growing yet underserved populations. The firm emphasizes the importance of combining capital with operational expertise to help startups succeed.

B2 Capital, based in London, is a cutting-edge asset management firm that integrates advanced technology and data-driven strategies to revolutionize the fields of ESG (Environmental, Social, and Governance), fintech, supply chain, and inventory finance. With a strong emphasis on innovation, B2 Capital positions itself as a disruptor in these sectors, utilizing a highly scalable tech platform that ensures bank-grade security while delivering agile, international financial solutions. The firm's leadership team brings together over 100 years of combined experience from leading names in the investment and technology sectors. The CEO & Co-CIO, Philip Blows, has a robust background in building and scaling asset management and fintech companies, having previously taken AQRU public in the UK. Co-CIO Dr. Philipp Kallerhoff, with his extensive experience in managing hedge funds and fintech enterprises, adds significant depth to B2 Capital's strategic capabilities. B2 Capital’s investment philosophy is centered around fostering "Diversity of Thought," aiming to deliver excellence to both clients and investors by identifying and funding innovative solutions that address global challenges, particularly in fintech and ESG. The firm’s approach is rooted in a strong commitment to creating the 'what next' in financing solutions, leveraging its advanced infrastructure to disrupt traditional finance models and promote sustainable growth. The firm’s dedication to innovation and its strategic focus on high-impact sectors position B2 Capital as a leader in the next generation of asset management.

Better Capital is a global venture capital firm that invests in early-stage startups across a variety of sectors. Founded by Vaibhav Domkundwar, the firm has a robust portfolio with over 200 companies, a combined valuation exceeding $7 billion, and two unicorns. They focus on backing bold innovators from day zero, emphasizing a conviction-driven investment approach. The firm has notable investments in fintech, health tech, SaaS, and digital education, with significant companies like Slice, Open, and Teachmint. Better Capital typically invests in pre-seed and seed rounds, with check sizes ranging from $300K to $1M. Their portfolio also includes companies like Rupeek, Khatabook, and Yulu, which are leaders in their respective fields. Geographically, Better Capital has a strong presence in India and the United States, with investments also spread across Singapore, the UK, and Australia. The team comprises experienced professionals who have founded, grown, and sold tech startups, providing valuable mentorship and support to the companies they invest in. Startups looking to engage with Better Capital should demonstrate innovative solutions with potential for significant impact and growth. The firm values mission-driven founders and aims to support them in creating industry-defining changes.

Better Ventures is a mission-driven VC firm investing in early-stage startups that harness cutting-edge technology to address pressing global challenges. Their notable investments include Meati, a sustainable protein innovator, and SMBX, a platform democratizing business financing. With a focus on sectors like climate tech, human health, and equitable economies, they back diverse teams aligned with the UN's Sustainable Development Goals. Based in Oakland, Better Ventures leads seed rounds, providing active support for founders committed to making a measurable impact. The team looks for companies that can scale profitably while driving social and environmental change, ensuring purpose and profit go hand-in-hand. Better Ventures prefers founders who blend technological innovation with a clear mission. They typically write checks of $500k to $1 million and often lead or co-lead rounds. The firm emphasizes strong partnerships, working closely with founders to scale their impact. Startups should approach Better Ventures with a well-defined purpose, as they prioritize purpose-driven innovation. The founding team includes Rick Moss and Jenny Kassan, both seasoned in impact investing and business development. Better Ventures' geographic focus spans the U.S., especially targeting hubs of innovation. Their approach to funding emphasizes scalability, sustainability, and measurable impact, creating value for both investors and society.

Beyond Next Ventures, founded in 2014 and based in Tokyo, focuses on early-stage investments in deep tech startups, primarily in Japan and India. The firm invests in various sectors including medtech, healthcare, biotechnology, agriculture, food, digital, space, and climate technology​. Notable investments include companies like MediBuddy, GigIndia, QD Laser, and Susmed. MediBuddy is a significant player in telemedicine and healthcare services in India, while QD Laser and Susmed are notable for their IPOs on the Tokyo Stock Exchange​. Beyond Next Ventures typically leads early-stage financing rounds, offering extensive support through their incubator programs aimed at commercializing advanced research. The firm has about $340 million under management, underscoring its commitment to fostering innovation in deep tech and science-based startups​. The leadership team, including CEO Tsuyoshi Ito and Managing Director Kengo Ueha, brings a wealth of experience and strategic insight, supporting startups through growth management, market entry, and expansion strategies.

Big Idea Ventures, founded in 2018, is a leading venture capital firm focusing on the alternative protein and food technology sectors. With over 110 early-stage investments, they have become the most active investor in FoodTech globally. The firm operates through its New Protein Fund and Generation Food Rural Partners fund, supporting innovative companies in plant-based, cell-based, and fermentation-enabled food technologies. Notable investments include companies like Naturannova, which creates sustainable peptide-based flavors using AI, and SoundEats, a cultivated seafood pioneer. Other standout portfolio companies are New Wave Biotech, which develops bioprocess optimization software, and Loki Foods, which produces plant-based seafood using renewable energy in Iceland. Big Idea Ventures runs bi-annual accelerator programs in New York, Paris, and Singapore, providing selected companies with a $200,000 investment and access to an extensive network of partners and investors. This hands-on support helps startups navigate product development, scaling, and market entry. Led by founder Andrew D. Ive, Big Idea Ventures collaborates with strategic partners like Temasek Holdings, Tyson Ventures, and Givaudan, aiming to drive significant advancements in food security and sustainability.

Big Pi Ventures is a venture capital firm based in Greece, focusing on seed and early-stage investments, particularly in deep-tech and science-driven startups. Established with a vision to drive transformative innovation, Big Pi partners with exceptional teams developing technologies that address significant global challenges. Their investments span various sectors, including artificial intelligence, health and life sciences, and climate technology, often targeting companies with strong intellectual property or technological advantages. The firm is anchored in Greece but maintains a global perspective, requiring that its portfolio companies establish substantial operations in Greece. Notable investments include companies like TileDB, Orfium, and Navenio, reflecting their commitment to backing ventures that have the potential to scale internationally. Big Pi is led by a team of seasoned entrepreneurs and investors, including Marco Veremis, co-founder of Upstream, and Alex Eleftheriadis, a pioneer in video compression technology. The team offers more than just capital, providing strategic support in areas like product design, scaling, and global market expansion. Their latest rebranding and new fund, announced in 2023, signify their ongoing commitment to fostering innovation and supporting the next generation of tech leaders.

BioAdvance is a prominent life sciences venture capital fund based in the mid-Atlantic region, focusing on therapeutics, diagnostics, medical devices, research tools, and health IT. With over 100 investments, they have achieved 23 exits and brought 12 FDA-approved products to market. Their portfolio companies, such as Palvella Therapeutics and Strados Labs, have attracted significant follow-on funding, collectively raising over $4.2 billion. BioAdvance operates as an evergreen fund, enabling continuous reinvestment and long-term partnership with entrepreneurs. The fund emphasizes capital efficiency and works closely with startups to maximize limited resources. Their investment strategy centers on advancing human health technologies with potential for high impact, targeting early-stage companies with scalable innovations. Led by a team of seasoned executives, scientists, and physicians, BioAdvance is collaborative, often playing an active role in company growth and guiding entrepreneurs toward successful exits via IPOs or acquisitions. They prefer to engage with startups that have a strong business case and well-developed pitch, ensuring a strong fit with their mission of improving human health.

Bioeconomy Capital is a San Francisco and Seattle-based venture capital firm founded in 2015. The firm focuses on early-stage investments in biotechnology, life sciences, and sustainability technology. Bioeconomy Capital is driven by the goal of accelerating the biotechnology revolution by supporting companies that are developing critical infrastructure and innovative technologies for the 21st century. With a strong foundation in synthetic biology, Bioeconomy Capital leverages decades of expertise in life sciences and engineering to back startups with transformative potential. The firm’s portfolio includes notable companies such as Zymergen, Riffyn, Synthace, RoosterBio, and Arzeda. Bioeconomy Capital typically invests between $100K and $5M, with a sweet spot of $1.5M per investment. The firm has a global focus, primarily investing in the U.S. but occasionally supporting companies in the U.K. and other regions. Led by managing directors Rob Carlson and Rik Wehbring, Bioeconomy Capital plays a strategic role in helping its portfolio companies navigate the complexities of scaling biotech and sustainability solutions​.

BioGeneration Ventures (BGV) is a prominent venture capital firm based in Naarden, Netherlands, specializing in early-stage European biotech companies. With over €400 million under management, BGV focuses on sectors like biopharma, medtech, and diagnostics. Their portfolio features notable investments in companies such as AcertaPharma, argenx, and New Amsterdam Pharma, underscoring their success in advancing groundbreaking scientific innovations and addressing unmet medical needs. BGV typically engages in seed to early growth stages, strategically guiding companies through clinical trials and drug development to achieve substantial exits. Their rigorous selection process ensures they back ventures with the highest potential for impactful outcomes. BGV's investment philosophy centers on combining deep scientific expertise with commercial insight to build world-class biotech firms. The firm is led by a team of experienced professionals, including managing partners Edward van Wezel and Suzanne Morsink, who bring extensive backgrounds in life sciences and venture capital. They actively support portfolio companies with strategic guidance, leveraging their broad network and industry knowledge to drive growth and innovation. BGV is committed to fostering the next generation of biotech leaders, with a clear focus on creating value for both investors and society by addressing critical health challenges through cutting-edge science and technology

BioMedPartners, through its BioMedInvest funds, focuses on venture capital investments in early to mid-stage companies in the biotechnology, pharmaceutical, and medical technology sectors. Based in Basel, Switzerland, the firm supports innovations primarily in the Alpine region and other European markets. Notable portfolio companies include Aleva Neurotherapeutics, developing next-generation implants for deep brain stimulation; Anergis, which focuses on peptide-based immunotherapies for allergies; and Evolva, a biotech firm creating sustainable ingredients for health and nutrition. Additionally, BioMedPartners has invested in companies like Hookipa Biotech, which develops novel immunotherapies for infectious diseases and cancer, and Sequana Medical, specializing in implantable fluid management systems. The BioMedPartners team is led by General Partners such as Dr. Markus Hosang and Dr. Michael Wacker, who bring extensive experience in drug development, finance, and technology. The firm takes an active role in the development of its portfolio companies, often leading investment rounds and participating as a syndicate partner​.

Bioqube Ventures is a specialist life sciences venture capital firm focused on early-stage investments in Europe, particularly in therapeutic assets and disruptive healthcare technologies. Founded in 2016 by Debora Dumont and Nico Vandervelpen, the firm launched its independent fund, Bioqube Factory Fund I, in 2020. This fund, which has secured over €60 million in its initial closing, aims to support the development of breakthrough therapies by leveraging Bioqube's unique dual investment model. This model includes both traditional venture investments and a "Create" strategy, which focuses on de-risking projects before establishing new ventures. The fund's strategy is deeply rooted in supporting high-potential scientific innovations, transforming them into commercially viable biotechnologies. Bioqube has strong partnerships with prominent investors like the European Investment Fund, Johnson & Johnson Innovation, and Genmab, further bolstering its ability to drive significant advancements in the life sciences sector. The Bioqube team is composed of experienced fund managers, sector experts, and serial entrepreneurs, bringing a hands-on approach to guiding portfolio companies through their growth stages. The firm has a significant presence in Europe, with a focus on regions such as the Benelux, France, and Germany, aiming to build a new generation of leading biotech companies.

BioRock Ventures is a Palo Alto, California-based seed-stage venture capital firm founded in 2019, dedicated to accelerating the development of novel medicines. The firm invests in early-stage biopharmaceutical companies developing novel FDA-regulated therapeutic drugs, covering all disease areas, development stages, and therapeutic modalities. BioRock operates two funds — BioRock Ventures I and Fund II — and leads rounds with checks up to $2 million at angel, seed, and Series A stages. The firm is led by Dr. Mary Wheeler, PhD, MBA, Founding Managing Partner, with over two decades of experience in the therapeutics startup sector. With 15 investments concentrated in biotech and pharma, BioRock's portfolio includes Immusoft (gene-modified B cell therapies for rare diseases), Primmune Therapeutics, and Veana Therapeutics — all working within drug discovery and early-stage clinical development. The firm focuses on companies addressing unmet medical needs with scientifically rigorous approaches, prioritizing therapeutic innovation over platform plays. BioRock Ventures leads its rounds, positioning itself as a conviction-driven, science-first investor at the earliest stages of biopharmaceutical company formation. Dr. Wheeler's deep operating background in therapeutics startups allows the firm to evaluate scientific merit with the rigor of an insider, not just a financial analyst. For founders navigating the early challenges of building biopharma companies — from IND-enabling studies through seed fundraising — BioRock provides both capital and an experienced scientific partner committed to the long development timelines that novel therapeutics require.

Bioverge is a venture capital firm and investment platform specializing in early-stage healthcare startups. Based in San Francisco, Bioverge provides accredited investors with opportunities to invest in innovative healthcare companies that aim to transform the industry. The platform leverages deep domain expertise and a robust network to offer exclusive access to premier healthcare startups, ensuring that investments have both high impact and the potential for significant returns. Bioverge Funds, such as the Bioverge Access Fund, allow investors to diversify their portfolios by investing in a curated selection of healthcare startups through a single investment. These funds provide preferred access to deals, discounted fees, and the benefit of spreading investment risk across multiple companies. Bioverge emphasizes a data-driven investment approach, utilizing AI to select the most promising opportunities in the healthcare sector. Notable investments by Bioverge include companies like Enveda, which focuses on developing next-generation small-molecule therapeutics, and JelikaLite, which has created a non-invasive therapy for children with autism. Bioverge's investment strategy aims to support startups that offer groundbreaking solutions in healthcare, biotechnology, and medical technology. The firm was founded by Neil Littman, who brings extensive experience in healthcare venture capital. Bioverge's mission is to democratize access to high-quality healthcare investments, providing individual investors with the same opportunities as institutional investors.

BIP Ventures, previously known as Panoramic Ventures, is an Atlanta-based VC firm known for its mission of investing in underserved markets and underrepresented founders. With over $550 million in assets under management, BIP Ventures focuses on funding early-stage and growth-stage companies, particularly in the B2B software, healthcare, fintech, and tech-enabled services sectors. The firm takes a unique approach by targeting investments in regions often overlooked by traditional VCs, such as the Southeast and Midwest, and promoting diversity in its portfolio, prioritizing racial and gender inclusion. In addition to capital, BIP Ventures offers strategic support, including talent acquisition, operational scaling, and infrastructure to help portfolio companies grow into market leaders. The team, led by Mark Buffington and Paul Judge, consists of experienced investors and operators who have collectively backed over 200 startups, with several notable exits. The firm is also active in fostering innovation through university partnerships, investing in startups originating from academic institutions. BIP Ventures is known for initiatives like its Startup Showdown pitch competitions, which provide early-stage companies with funding opportunities. Entrepreneurs partnering with BIP Ventures benefit from a hands-on approach, with mentorship and resources to accelerate growth.

Bits x Bites is a Shanghai-based venture capital firm and China’s first dedicated agrifood tech investor. Founded in 2016 by Matilda Ho, the firm focuses on early-stage startups tackling the most critical challenges in the food system, including food security, safety, and sustainability. Their investments span the entire food supply chain, from farm innovations to novel food production technologies, helping to revolutionize agriculture in China and beyond. Bits x Bites manages over $100 million across its funds, with a strong emphasis on scalable technologies that can make a measurable impact on food production and environmental sustainability. Their portfolio includes companies like EAVision, which specializes in autonomous drones for complex farming terrains, and Mojia Bio, a biomanufacturing startup that produces eco-friendly nutrients for the food industry. These investments reflect the firm’s commitment to advancing solutions in precision agriculture, alternative proteins, and biomanufacturing. With a global outlook, Bits x Bites evaluates around 1,200 startups annually, targeting companies with technologies that can be applied in China. They support their portfolio companies through partnerships with industry leaders such as Syngenta and Temasek, offering access to valuable resources and markets. The firm’s multidisciplinary team of experts provides hands-on guidance to help startups scale and commercialize their innovations in the Chinese market, shaping the future of food technology in the region​.

Black Pearls VC is an early-stage venture capital firm based in Gdańsk, Poland, with a strategic focus on the Baltic Sea Region and Central Europe. They are particularly keen on deep tech startups developing unique, scalable technologies. The fund supports businesses from seed to Series A stages, with initial investments ranging from €100k to €1m and follow-on investments up to €3m. The firm has a sector-agnostic approach but has made significant strides in digital health, enterprise software, fintech, and deep tech. Notable portfolio companies include Nanoxo, a developer of non-toxic quantum dots for various industries; Xopero, specializing in data protection solutions; and Prosoma, which offers digital therapeutics for cancer patients​. Black Pearls VC's investment strategy emphasizes collaboration, often co-investing with other prominent funds. They focus on backing entrepreneurs with groundbreaking ideas and providing extensive support through their global network of advisors and partners. The team includes experts like Managing Partner Marcin P. Kowalik, who brings a wealth of experience in corporate finance and investment management. For startups looking to attract Black Pearls VC, it is essential to highlight the scalability and uniqueness of their technology. Approaching them through detailed pitches that align with their deep tech focus can significantly increase the chances of securing funding.

Blackbird Ventures is a prominent venture capital firm based in Australia and New Zealand, known for its early-stage investments in startups with high ambitions and potential for generational impact. Founded in 2012, Blackbird has backed over 100 companies, including well-known names like Canva, Zoox, SafetyCulture, and Culture Amp. The firm is sector-agnostic, investing across various industries, from software to space technology. Blackbird's investment philosophy emphasizes supporting founders from the earliest stages, before revenue or product, through their entire journey to IPO and beyond. This approach has led to substantial success, with a portfolio valued at over $7 billion and several companies exceeding $1 billion in valuation. Blackbird is also committed to building a robust community around its portfolio companies, offering programs like Giants, a mentoring initiative, and The Sunrise festival, which fosters a vibrant startup ecosystem. Their team consists of experienced investors and industry professionals dedicated to helping founders achieve their wildest ambitions.

Blackhorn Ventures is an early-stage venture capital firm that focuses on investing in companies that drive industrial efficiency and environmental sustainability. The firm targets sectors such as energy, construction, supply chain logistics, and transportation. Some of the notable portfolio companies include Aperia, which develops tire inflation systems for trucks; Agorus, known for building custom homes quickly and precisely; and Electric Era, which creates advanced energy storage systems for EV charging stations. Blackhorn Ventures employs a capital-efficient approach, leveraging AI and digital solutions to modernize traditional industries and improve operational efficiency. The firm is deeply committed to decarbonizing industry sectors and aligning investments with environmental sustainability goals. The firm is led by experienced investors and operators who focus on creating value and engaging collaboratively with their portfolio companies and strategic partners to achieve both financial returns and impactful outcomes.

Blindspot Ventures is a seed-focused venture capital firm based in Boston, specializing in backing visionary founders who are reshaping industries through platform technologies and infrastructure innovation. The firm is known for partnering with bold, iconoclastic entrepreneurs who challenge the status quo and develop foundational technologies that drive industry evolution. Their portfolio includes cutting-edge companies like Form Energy, Mori, bloXroute, and Volta Labs, all of which are pioneers in fields ranging from renewable energy storage to advanced material science. Blindspot primarily invests in early-stage companies, with a typical check size of $500K to $3M. Their geographic focus is predominantly on the U.S., leveraging Boston’s rich history of innovation and proximity to top-tier academic institutions. Blindspot actively supports its portfolio companies, often taking board seats and offering strategic advice to foster long-term partnerships. Led by managing partners Ahmed Hentati and Hassan Dayekh, Blindspot is driven by a passion for addressing critical global challenges. Hentati, deeply ingrained in Boston’s startup ecosystem, focuses on identifying and backing groundbreaking founders, while Dayekh manages operations and co-leads the investment committee, bringing extensive experience from his background in banking and growth-stage venture capital.

Bling Capital is a venture capital firm specializing in seed-stage investments, founded by Ben Ling, who has a strong track record with 19 "unicorn" investments. The firm focuses on helping entrepreneurs achieve product-market fit and scale their businesses. Bling Capital has recently announced the closing of its third fund, raising $212 million, which includes a $109 million core seed fund and a $103 million opportunity fund to support companies as they grow. The firm's investment strategy targets sectors such as B2B software, consumer tech, digital health, fintech, and the future of work. Bling Capital typically invests around $1 million at the seed stage and provides extensive support through its Product Council, which comprises over 100 top product leaders from various industries. Notable companies in Bling Capital's portfolio include Lyft, Palantir, Lucidchart, Udemy, Gusto, and Instacart. The firm is dedicated to partnering with high-potential founders and supporting them through every stage of their journey.

Bloc Ventures is a specialist deep tech investor founded in 2013 by Bruce Beckloff and David Leftley, both veterans of ARM and Vodafone. The firm focuses on early-stage investments in European deep tech companies, particularly those working in cloud computing, connectivity, data science, and security. They aim to support ambitious entrepreneurs building products with the potential to impact entire industries. Bloc Ventures has a robust portfolio of companies, including Helix Geospace (precision antennas), Mindtrace (AI software), Paytia (cloud-based PCI compliance solutions), Pharrowtech (RF semiconductor technology), and Shield-IoT (IoT security platform). These investments highlight Bloc's commitment to advancing technologies that enable significant industry advancements. The firm recently raised over €23.9 million to fund early-stage deep tech startups in Europe, led by IPGL Limited and supported by industry leaders. This funding will support new portfolio additions and follow-on investments, aligning with Bloc’s strategy to scale companies of global significance. Bloc Ventures is headquartered in London and is recognized for its expert-led funding approach, combining technological, commercialization, and financial expertise to help startups reach their full potential. The team includes professionals with extensive backgrounds in the tech industry, venture capital, and company management, ensuring a hands-on and supportive partnership for their portfolio companies​

Bloomberg Beta, an early-stage venture capital firm launched in 2013, manages $375 million in total across several funds. Backed solely by Bloomberg L.P., the firm focuses on investing in startups that aim to improve the future of work, emphasizing machine intelligence and data-centric technologies. Notable investments include companies such as Repl.it, a cloud computing platform for developers; LaunchDarkly, which helps software teams build better software faster; and StrongDM, an infrastructure access platform. Bloomberg Beta has also had significant exits, including Rigetti Computing, Orbital Insight, and Flashpoint​. The firm operates independently from Bloomberg L.P., and its team, led by Roy Bahat, Karin Klein, and James Cham, employs a unique investing model where any team member can independently approve deals. They maintain a strong commitment to transparency, with their operating manual and investment criteria publicly available on GitHub​​. Bloomberg Beta supports entrepreneurs through various stages of growth, leveraging data to identify potential founders and emphasizing a collaborative approach to investment. Their investment strategy is broad, focusing on startups that can bring transformative changes to how businesses operate and how people work

Blue Chip Venture Company is Cincinnati, Ohio's first resident venture capital fund, founded in 1990 and one of the longest-running VC firms in the Midwest. Over more than three decades and six funds, the firm has invested over $600 million in more than 150 companies spanning internet media, consumer marketing, software, healthcare, pharmaceuticals, and traditional manufacturing. Blue Chip is headquartered at 250 E. Fifth Street in Cincinnati and has been a cornerstone of the Ohio startup ecosystem since its founding. The firm leads rounds at Series A through later stages, with checks typically between $3 million and $20 million, and has made 153 total investments across its primary sectors of software, health technology, digital media, and data analytics. Blue Chip specializes in providing 'last financing round' or 'pre-exit' capital for early-stage investors and venture-backed companies — rounds structured to strengthen a company's balance sheet and bridge it to a near-term liquidity event. Portfolio companies include Scale Computing, Aprecia (3D-printed pharmaceutical drug delivery), and Emata. Blue Chip Venture Company's 35-year operating history gives it a perspective on company building through multiple economic cycles that few Midwestern investors can claim. The firm's focus on digital media, big data, and technology companies reflects the evolution of its thesis over decades while maintaining its core commitment to the Cincinnati and broader Ohio technology ecosystem. For founders seeking experienced, regionally committed venture partners with a demonstrated record of supporting companies to exit, Blue Chip represents an anchor institution in Midwest venture capital.

Blue Horizon is a Zurich-based venture capital firm focused on investing in the future of food. Founded in 2016 by Bjoern Witte and Roger Lienhard, the firm has established itself as a leader in the sustainable food sector, managing over $850 million in assets and investing in more than 60 companies globally. The firm primarily targets the alternative protein and food technology industries, with notable investments in companies like Impossible Foods, Mosa Meat, and Planted. These investments reflect Blue Horizon's commitment to pioneering innovations that promote sustainability and environmental responsibility. Mosa Meat, for instance, developed the world’s first lab-grown beef burger, while Planted is a notable player in the vegan meat market. Blue Horizon’s investment strategy emphasizes a full lifecycle approach, supporting companies from seed stage through to significant growth phases. They focus on businesses that offer transformative solutions to global challenges in the food system, such as reducing reliance on traditional meat and dairy production, and promoting plant-based and cultured food alternatives. For startups looking to connect with Blue Horizon, demonstrating a strong alignment with their mission of creating a sustainable food system and showcasing innovative solutions that address significant market opportunities are key to forming a successful partnership.

Blue Ocean Partners, managed by SWEN Capital Partners, is a pioneering venture capital firm dedicated to restoring ocean health through impactful investments. Launched in 2021, Blue Ocean has quickly become the world’s largest ocean-focused venture fund, closing at €170 million in 2023, far exceeding its initial target of €120 million. The fund targets startups that are developing innovative solutions to combat key challenges facing the oceans, including overfishing, pollution, and climate change. The fund’s portfolio includes a diverse range of companies that are driving significant environmental impact. For example, ECOsubsea offers environmentally friendly in-water hull cleaning services that reduce carbon emissions and prevent the spread of invasive species. Another portfolio company, BlueNav, develops hybrid electric propulsion systems that help reduce the carbon footprint of marine transportation. Additionally, Avant is pioneering the production of cultivated seafood, offering a sustainable alternative to traditional fishing practices. Blue Ocean Partners is committed to generating both financial returns and measurable environmental outcomes. The fund’s investments are aligned with global efforts to regenerate marine ecosystems and contribute to the broader movement of sustainable ocean innovation. As a co-founder of the 1000 Ocean Start-ups initiative, Blue Ocean Partners plays a key role in scaling transformative ocean-focused technologies globally, further solidifying its leadership in the ocean impact investing space.

Blue Venture Fund (BVF) is the corporate venture capital arm of the Blue Cross Blue Shield Association, headquartered in Chicago, Illinois. Founded in 2008, BVF operates as a unique collaboration among 35 Blue Cross Blue Shield companies, the BCBS Association, and Sandbox Industries, which provides investment management services. Thirty-five BCBS companies have committed over $890 million across four funds, making it one of the largest healthcare-focused corporate venture platforms in the United States. Managing Directors include Tom Hawes and Jeff Carroll. BVF has made 149 investments and achieved 33 portfolio exits, investing in venture and growth opportunities in healthcare technology, healthcare services, and clinical sciences. Checks typically range from $3 million to $20 million across Series A through later stages. Portfolio companies include Big Health, Daymark Health, Alacura, Bluestone Physician Services, CirrusMD, Origin, and Nest Health. The most recent investment was Big Health's $23.7 million Series D in February 2026, alongside .406 Ventures, AlleyCorp, and CVS Health Ventures. Blue Venture Fund's strategic model connects portfolio companies directly to the knowledge, clinical expertise, and market access of 35 Blue Plan partners — a network covering a majority of insured Americans. For health technology companies seeking to prove commercial viability within the payer ecosystem, this access is structurally significant: it enables portfolio companies to conduct pilots, gather real-world evidence, and build distribution relationships with some of the largest healthcare purchasers in the country, accelerating both clinical validation and commercial scale.

Blue Wire Capital, established in 2013, is a London-based venture capital firm that focuses on early-stage investments, particularly in the pre-seed and seed stages. The firm invests across industries such as business software, environmental services, and educational technology. Notable portfolio companies include Climate X, Five, and Praktika.ai. Geographically, their investments are concentrated in Europe, with a strong presence in London. Blue Wire Capital's strategy emphasizes supporting visionary entrepreneurs addressing global challenges through technology. They typically lead investment rounds, with average check sizes around $5.96 million. They are active, engaging in 2-6 deals annually, and maintain a flexible approach to capital deployment. The team includes Bertie Highmore, Head of Investments, who brings experience from Goldman Sachs and Susquehanna International Group. To approach Blue Wire Capital, startups are advised to demonstrate innovative solutions with significant impact potential. The firm values fast and flexible access to capital, providing not just funding but also strategic support and networking opportunities to foster entrepreneurial success.

Blue Haven Initiative is a pioneering family office focused on combining competitive financial returns with deep social and environmental impact. Co-founded by Liesel Pritzker Simmons and Ian Simmons in 2012, it manages a diverse portfolio across asset classes including public equities, private equity, fixed income, and direct investments. The initiative targets sectors such as clean energy, financial inclusion, and healthcare, with notable investments in companies like CrossBoundary, PEG Africa, and M-Kopa. Geographically, Blue Haven has a significant focus on Sub-Saharan Africa, where it supports early-stage businesses that create economic opportunities and improve living standards in underserved communities. Their strategy includes not only market-rate investments but also philanthropic efforts, policy advocacy, and coalition-building to drive systemic change. As an active early-stage investor, Blue Haven often leads rounds, leveraging its flexibility as a family office to deploy catalytic capital where needed. Ian Simmons, a champion of long-term, impactful investing, leads the team from their headquarters in Cambridge, Massachusetts, working closely with external partners to maximize both financial and social returns.

BlueOcean Ventures is a Geneva, Switzerland-based venture capital firm founded in 2007 by four partners — Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz, and Thomas Zehnder — who collectively bring decades of experience building, managing, and coaching high-tech startups. The firm concentrates exclusively on early-stage medical device and life science companies across Europe, deploying check sizes of $1 million to $5 million at seed and early stages across 23 investments to date. BlueOcean leads rounds and has backed companies spanning healthtech, biotech, and diagnostic robotics. Fund II — which became the first tokenized medtech VC fund through its STO platform SwissVCToken — invested in five companies: Ava (named Switzerland's best startup in 2017/2018), Rheon Medical (adjustable glaucoma drainage device), Volumina Medical, Luciole Medical, and Abionic. Other portfolio companies include MIKAJAKI (ophthalmic diagnostic robotics, CHF 2.4M+ pre-Series A), nPloy, and CyanoGuard. Co-founder Sacha Haymoz previously co-founded PharmARC, a 300-person firm sold to IMS Health in 2012; Emmanuel de Watteville has coached over 200 high-tech startups since 2003. BlueOcean Ventures targets untapped market segments where capital scarcity and clinical complexity create a barrier that experienced domain partners can bridge. The firm supports portfolio companies with an extensive expert network and industry contacts, aiming to place capital where it addresses unmet medical needs rather than crowded, well-funded niches.

BlueRun Ventures (BRV), founded in 1998 and headquartered in Menlo Park, CA, is an early-stage venture capital firm with a global presence. The firm has offices in the United States, China (Beijing and Shanghai), and South Korea. BRV is known for its focus on mobile, fintech, digital health, and consumer experiences, targeting startups that solve significant problems in these sectors. BRV's portfolio boasts notable investments including PayPal, Waze, Coupa, and Kabbage, showcasing their track record in identifying and nurturing high-potential companies. The firm’s investment strategy involves leading seed and Series A rounds, typically investing between $2 million and $8 million per deal. They prioritize early-stage companies that exhibit strong growth potential and innovative solutions. The BRV team consists of experienced professionals such as co-founders John Malloy and Jonathan Ebinger, who bring deep expertise in mobile software, services, and financial technology. The team leverages its collective experience in product development, marketing, and design to support portfolio companies. Startups looking to engage with BRV should emphasize their potential for disruption and scalability. The firm values entrepreneurs who are pushing industry boundaries and can benefit from BRV’s extensive network and hands-on approach to growth.

BlueYard Capital is a venture capital firm that invests in early-stage companies with transformative potential across various industries. Established to support innovative founders, BlueYard focuses on creating a future where markets are open and decentralized, significant planetary challenges are addressed, and knowledge and data are liberated. The firm is known for its thematic investments in sectors like blockchain, crypto, artificial intelligence, web3, and biotechnology. BlueYard has a diverse portfolio that includes companies such as Bit Bio, Meatable, and Biofidelity, which are involved in biotechnology and healthcare innovations. The firm also invests in blockchain and crypto platforms like Centrifuge and Agnostic, aiming to revolutionize data management and financial systems. The firm's investment strategy emphasizes backing open-ended, breakthrough research and early-stage startups. BlueYard's portfolio companies benefit from its extensive network, strategic guidance, and a supportive investment environment that fosters innovation and growth.

Blumberg Capital is an early-stage venture capital firm that invests in startups from inception through growth stages. With over $650 million in assets under management, the firm focuses on sectors such as fintech, AI, cybersecurity, enterprise software, and digital health. Blumberg Capital has been a key player in supporting companies that use transformative technologies to empower individuals and businesses. Notable investments include Nutanix, BioCatch, and DoubleVerify, demonstrating their success in various tech-driven industries. Additionally, Blumberg Capital has heavily invested in fintech companies, making up about 29% of their portfolio. Key fintech investments include Fundbox, Lendio, and Addepar. The firm is known for its hands-on approach, providing not just capital but also strategic support, leveraging its extensive network and expertise to help startups succeed. Blumberg Capital's investment strategy involves leading seed and Series A rounds, with initial investments ranging from $500,000 to $5 million. They are committed to partnering with visionary entrepreneurs and helping them navigate the challenges of scaling their businesses. The firm operates internationally, with offices in Miami, New York, San Francisco, and Tel Aviv. Their approach and successful track record make Blumberg Capital a prominent player in the venture capital landscape, supporting innovative companies that are shaping the future through technology​.

bmp Ventures is a seasoned venture capital firm based in Berlin, Germany, with over 25 years of experience in early-stage and growth investments. Since its founding in 1997, bmp Ventures has managed 11 venture capital funds and made more than 250 investments, resulting in over 120 exits and more than 20 IPOs. The firm focuses on investing in innovative and scalable companies across various sectors, including digital solutions, industry & deeptech, media & gaming, life sciences & eHealth, cleantech & planet positive, mobility & automotive, and fintech & legaltech​. They typically invest between €350,000 to €3 million in seed and early-stage rounds, with the potential to invest up to €10 million per company through subsequent financing rounds. bmp Ventures is known for being a hands-on investor, providing extensive support to their portfolio companies. This includes strategic advice, networking opportunities, assistance with business model refinement, and guidance on fundraising and exit strategies​.

The Boehringer Ingelheim Venture Fund (BIVF) is a €350 million evergreen corporate venture fund of Boehringer Ingelheim, one of the world's largest family-owned pharmaceutical companies. Founded in 2010 and headquartered in Ingelheim am Rhein, Germany, with additional offices in the United States and China, BIVF invests in groundbreaking, therapeutics-focused biotechnology companies to drive innovation in biomedical research. The fund's capital base has grown substantially since inception, more than doubling through successive expansions that reflect Boehringer Ingelheim's deepening commitment to external innovation. BIVF leads rounds from seed through Series B, deploying checks between $3 million and $30 million, and has built a portfolio of over 40 companies with 6 exits back to the Boehringer Ingelheim parent. The fund's scientific focus spans first-in-class, disease-modifying therapeutics across immuno-oncology, regenerative medicine, infectious diseases, and digital health. The investment thesis prioritizes unprecedented therapeutic concepts addressing high medical need rather than incremental improvements on existing mechanisms. BIVF's evergreen structure distinguishes it from fund-cycle-constrained investors, allowing it to support portfolio companies across the extended development timelines that novel therapeutics require. The fund's global presence across Europe, the US, and China enables it to source and support biotechnology innovation wherever it originates. Portfolio companies benefit from Boehringer Ingelheim's deep expertise in clinical development, regulatory affairs, and pharmaceutical manufacturing — resources that can meaningfully accelerate the translation of early science into approvable therapies.

Bold Capital Partners is a venture capital firm based in Santa Monica, California, with an additional office in Boston, Massachusetts. Founded in 2015 by Peter Diamandis, the firm focuses on investing in groundbreaking technologies and innovative companies that aim to solve humanity's biggest challenges. Their investment strategy targets sectors including advanced robotics, AI, healthcare, and sustainable technologies. Notable portfolio companies include Rugged Robotics, which provides automated construction solutions, and Mighty Buildings, which focuses on sustainable 3D printing for construction. Bold Capital Partners supports startups at various stages, from seed funding to growth stages, emphasizing disruptive potential and significant market impact. The team at Bold Capital Partners includes experienced professionals such as Managing Partner Teymour Boutros-Ghali, General Partner Emilio Diez Barroso, and Operating Partner Helen McBride, who bring a diverse range of expertise in investment and entrepreneurship. They leverage their extensive network and industry knowledge to provide strategic support to their portfolio companies. Bold Capital Partners is committed to uplifting humanity through strategic investments in technologies that democratize and transform major markets​.

Bolt is a pre-seed venture capital firm that invests in startups operating at the intersection of the digital and physical worlds. Founded in 2012, Bolt focuses on companies leveraging innovative technologies and valuable data sets to reimagine products, systems, and experiences. The firm is known for leading the first round of financing in over 90% of its investments, which often include unique hardware and software combinations​. Bolt's portfolio includes notable companies like Tonal, Desktop Metal, Pair Eyewear, and Tive. These companies span various sectors, showcasing Bolt’s commitment to supporting a diverse range of innovative startups​​. The firm operates from Boston, Massachusetts, and is led by experienced partners such as Axel Bichara, Greg McAdoo, Kate McAndrew, Matt Thoms, and Tyler Mincey, all of whom bring extensive backgrounds in venture capital and entrepreneurship. Bolt also engages with the startup community through initiatives like Women in Hardware, a community supporting women and non-binary individuals in hardware development, and Groundwork, a workshop series for direct-to-consumer (DTC) founders.

Bonfire Ventures is a venture capital firm based in Santa Monica, California, founded in 2017 by Mark Mullen and Jim Andelman. The firm specializes in seed-stage investments in B2B software companies, aiming to support founders with significant ambitions in the tech space. Bonfire Ventures' strategy involves making initial investments ranging from $1 million to $5 million, often leading the first institutional round for their portfolio companies. The firm has raised multiple funds, including a $168 million third seed fund and a $63 million second opportunity fund, totaling $231 million in 2022. Bonfire Ventures has built a strong portfolio of over 198 investments, including notable companies like TaxJar, The Trade Desk, and Boulevard. Bonfire Ventures is known for its deep commitment to its portfolio companies, providing not just capital but also strategic guidance and operational support to help startups scale successfully. The team includes experienced professionals like Brett Queener, Jennifer Richard, and Brian MacInnes, who bring a wealth of industry knowledge and expertise to their roles.

Boom Capital, founded in 2016 by Celestine “Cee Cee” Schnugg, is a San Francisco-based venture fund focused on early-stage investments in cutting-edge scientific fields. The firm specializes in deep tech sectors, including healthcare, genomics, machine intelligence, aerospace, and innovative chemistry. Boom Capital's unique value proposition is its deep integration into the scientific community, giving it first access to groundbreaking companies born from frontier science. Leveraging a network of top-tier scientists, including Nobel Prize winners, the firm is positioned to partner with founders long before their ideas are widely recognized. Boom Capital has a track record of identifying transformative technologies early and providing significant support in terms of capital and mentorship. Its portfolio boasts notable companies such as Mammoth Biosciences, Diligent Robotics, Fauna Bio, and A-Alpha Bio, all leaders in their respective fields. The firm has also seen several successful exits, including Planet Labs and Swarm Technologies—the latter being acquired by SpaceX. With a focus on accelerating the journey from research to commercialization, Boom Capital is committed to nurturing the “scientist-protagonists” who are pushing the boundaries of innovation. Its mission is to support high-impact founders with transformative potential, often before traditional investors take notice. By offering not only capital but also access to a vast network of scientific and technical expertise, Boom Capital plays a crucial role in turning visionary ideas into successful ventures.

Boost VC, founded by Adam Draper and Brayton Williams in 2012, is a venture capital firm based in San Mateo, California, that focuses on early-stage investments in frontier technologies. With over $200 million in assets under management, Boost VC typically invests $500,000 in pre-seed startups, supporting over 300 companies. Their portfolio includes notable companies like Coinbase, Protocol Labs, and Snapcard, and spans deep tech sectors such as crypto, VR, AR, AI, space tech, robotics, and bio/health. Boost VC operates a rigorous accelerator program, providing startups with mentorship, resources, and networking opportunities. The three-month program offers intensive support from the Boost VC team and access to a wide network of industry experts and investors. The firm is known for its strong commitment to fostering innovation and diversity within the tech industry, actively supporting women and underrepresented founders. Adam Draper, a fourth-generation venture capitalist, and Brayton Williams, bring extensive experience and a vision for transformative technology startups. The team includes partners like Maddie Callander and Gus Domel, who offer diverse expertise from private aviation to brain health technology.

BootstrapLabs, established in 2008, is a leading venture capital firm based in San Francisco that focuses on investing in early-stage startups, particularly those leveraging Applied Artificial Intelligence (AI). The firm was one of the first to adopt an AI-first investment strategy in 2015. Since then, BootstrapLabs has been dedicated to backing visionary founders who tackle significant and valuable opportunities through AI across various sectors including Future of Work, Mobility, Health, Finance, Cybersecurity, Energy, and Climate. Their portfolio includes notable companies such as unitQ, GetAccept, and Hayden AI. BootstrapLabs prides itself on not only providing financial support but also offering strategic guidance by working closely with top AI talent and domain experts to ensure the growth and success of their portfolio companies. This approach has led to successful exits like AEye, Corpay One, and INDUS.AI. BootstrapLabs is known for making seed-stage investments, typically focusing on startups with the potential to create significant impact both financially and socially. The firm emphasizes that it is possible to achieve strong investment returns while also driving positive change for millions of people.

Borealis Ventures is a venture capital firm based in Hanover, New Hampshire, founded in 2002, with a singular focus on transforming healthcare through new therapies, digital innovation, and enabling technologies. The firm invests in life sciences, digital health, and animal healthcare, typically deploying $250,000 to $750,000 per company. Borealis has made 87 investments across five funds — including the Vox Health Fund — and has achieved 24 portfolio exits. The firm leads rounds and maintains a close relationship with the Dartmouth and Tuck academic ecosystem. Notable exits include Glaukos (medical technology for glaucoma) and Repligen (bioprocessing life sciences). Recent portfolio companies include ASTRA Therapeutics, Jenga Biosciences, Triveni Bio, and OvaInnovations (exit recorded November 2024). The data-driven, thematic approach has produced over 50 executed deals across multiple healthcare sub-verticals. Borealis is led by co-founder and Partner Phil Ferneau, who leads healthcare investing, alongside Partners Ben Shaw and Julia Stephanus. The team's collective background in healthcare investment and proximity to New England's research institutions enables early access to academic spinouts and clinician-founded companies at the pre-institutional stage. Borealis places particular emphasis on backing founders who are advancing genuinely differentiated science or platform technologies, rather than incremental product improvements.

Boro Capital is a New York-based venture capital firm that focuses on investing in pre-seed and seed-stage startups across various tech sectors. Established in 2017, the firm targets industries like fintech, SaaS, AI, big data, proptech, and cleantech, among others. Boro Capital’s investment approach centers on identifying early-stage tech companies with the potential to scale rapidly. They leverage a network of strategic partnerships with leading investor groups and accelerators, which helps them source high-potential, pre-vetted startups, streamlining their investment process. The firm typically invests in a company’s first round of institutional funding, cutting checks in the pre-seed and seed stages. With a focus on tech-enabled solutions, Boro Capital has built a diverse portfolio, with over 30 investments in areas like financial software, logistics, and biotechnology. Notable investments include companies like DetraPel, Michroma, and Hailify. Boro Capital’s strategy emphasizes early-stage innovation, aiming to support entrepreneurs through the challenging early phases of scaling their companies. The firm’s portfolio reflects a broad industry focus, from AI and machine learning to climate tech and consumer products. Their approach is designed to capitalize on fast-evolving technologies, making them a key player in helping startups navigate the complex journey from ideation to growth​.

Bossanova Investimentos, often referred to as Bossanova Invest, is a prominent venture capital firm based in Brazil, specializing in pre-seed stage investments. Founded in 2011 by Pierre Schurmann and later joined by João Kepler, Bossanova has established itself as the most active micro-VC in Latin America. The firm focuses on B2B and B2B2C technology companies that are innovative, digital, and scalable​​. Bossanova has invested in over 1,200 startups across more than 1,000 companies, making it a significant player in the early-stage investment scene. Their portfolio includes notable exits such as Glovo, Upsie, and Shift​​. They employ a rigorous selection process and offer extensive support to their portfolio companies to ensure rapid growth and success. The firm's investment strategy revolves around startups that are over 1.5 years old, have found a problem-solution fit, and are already operational and generating revenue. They avoid investments in sectors that exclusively target government, e-commerce, games, or hardware that competes with existing portfolio companies​. Bossanova's network includes over 10,000 co-investors, founders, and partner companies, providing a robust ecosystem for startups to thrive. They also offer educational resources through platforms like Clubb.vc, which provides courses and materials on investment, innovation, and business development​​. In addition to traditional equity investments, Bossanova has introduced an innovative investment model via Cédula de Crédito Bancário (CCB), which allows investors to gain exposure to the startup ecosystem with capital protection and fixed returns​​. This approach aims to democratize access to venture capital investments, making it accessible to a broader range of investors.

Boulder Ventures, established in 1995, is a venture capital firm that focuses on investing in early-stage information technology and life sciences companies. With headquarters in Boulder, Colorado, and an office in the Mid-Atlantic region, the firm leverages decades-long relationships with entrepreneurs and investors to drive its investment strategy. Boulder Ventures has raised eight funds totaling approximately $429 million, with the most recent fund, Boulder Ventures VIII, closing at $58 million in 2022. The firm has a notable track record, having invested in 61 companies, leading to 28 exits and 10 IPOs​. Key investments by Boulder Ventures include companies like Array BioPharma (acquired by Pfizer for $11.8 billion), LeftHand Networks (acquired by HP), and Wall Street on Demand (acquired by Goldman Sachs). The firm’s portfolio is diverse, covering sectors such as software, IT services, storage and communications, and life sciences. Kyle Lefkoff, the founder and general partner, brings over 38 years of venture capital experience. His extensive background includes significant roles in guiding companies through critical growth stages and strategic exits​.

Bow Capital, established in 2016 and based in Menlo Park, California, is a venture capital firm that leverages its strong connection with the University of California system to access a rich ecosystem of academic and research resources. This partnership provides them with broad access to the UC's 2.6 million faculty, staff, students, and alumni, as well as numerous research centers and medical facilities​. Bow Capital invests primarily in early-stage startups, focusing on sectors such as artificial intelligence, machine learning, big data, and enterprise software. Their portfolio includes notable companies like Ambi Robotics, Heartex, and Linus Biotechnology. The firm aims to bridge the gap between academia and industry, helping to commercialize innovative technologies and scientific discoveries. The investment strategy at Bow Capital includes participating in pre-seed, seed, and Series A funding rounds. They emphasize not only financial support but also strategic guidance and operational expertise, leveraging their network of Silicon Valley founders and industry leaders to help startups grow and succeed​. Notable exits for Bow Capital include companies like RealtyShares, Rimeto, and Skylight, reflecting their ability to identify and nurture high-potential startups to successful outcomes.

BoxGroup is a prominent early-stage venture capital firm based in New York City, established in 2009 by David Tisch and Adam Rothenberg. The firm focuses on investing in pre-seed to Series A rounds, targeting sectors such as consumer technology, enterprise software, fintech, healthcare, life sciences, and marketplaces. BoxGroup has built a robust portfolio with notable investments in companies like Plaid, Airtable, Ro, Ramp, Warby Parker, and Harry’s. They are known for their early-stage support and have made over 600 investments, actively backing innovative startups with the potential to disrupt and define new market categories. BoxGroup typically invests between $50,000 to $250,000 per deal, emphasizing conviction in the founding teams they support. Their approach is geography-agnostic, although they have a strong presence in key tech hubs such as New York, Silicon Valley, and Los Angeles. The firm has also seen several successful exits, including high-profile IPOs and acquisitions. They aim to be one of the earliest and most supportive investors, providing strategic guidance and leveraging their extensive network to help startups grow and succeed.

BoxOne Ventures, established in 2018 and based in Montreal, Canada, is a venture capital firm that focuses on early-stage investments across diverse and impactful sectors. The firm invests in companies with strong technology platforms in areas such as biotechnology, computational biology, AI and data analytics, digital health, fintech, and food technology. BoxOne Ventures has built a robust portfolio featuring notable investments like Juvena Therapeutics, which raised $41M to advance therapeutic solutions. Other significant investments include companies like dfuse, a blockchain development platform, and Odd Burger, a plant-based fast food chain. The firm’s strategy includes backing talented entrepreneurs and innovative technologies that aim to make a positive difference globally. The team at BoxOne Ventures comprises experienced founders and investors who are deeply involved in the development and support of their portfolio companies. This hands-on approach helps startups navigate the challenges of scaling and achieving market success.

New Science Ventures (NSV), founded in 2004, is a venture capital firm that focuses on investments in life sciences and information technology. With offices in New York and London, NSV aims to leverage breakthrough science to create significant value. The firm has a diverse portfolio, investing in companies that utilize fundamental, science-based innovations to address large unmet needs. NSV's notable investments include Ventyx Biosciences, which raised $114 million to advance its pipeline of immunology programs, and Paragraf, a company that mass-produces graphene electronics. Other significant portfolio companies are Phase Four, which develops next-generation electric propulsion solutions for satellites, and NorthSea Therapeutics, which focuses on novel treatments for liver-related diseases​. The firm typically invests in early to mid-stage companies and supports them through crucial value inflection points to help them scale. Their investment strategy is grounded in strong intellectual property protection and a long-term view​.